Protocol Ledger

NCT06433219 · Phase II · COMPLETED

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Interventional Phase II clinical trial protocol NCT06433219 sponsored by EMD Serono / Merck KGaA in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-30 Enrollment: 63 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06433219
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)63 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06433219
Protocol FieldVerified Registry Value
NCT IdentifierNCT06433219
Consolidated Lead SponsorEMD Serono / Merck KGaA
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment63 participants (ACTUAL)
Registered Start Date2024-10-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI